Published in
Springer, International Journal of Hematology, 3(111), p. 409-416, 2019
DOI: 10.1007/s12185-019-02802-y
Links
Tools
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma
Journal article published in 2019 by
Koji Izutsu 
,
Yosuke Minami,
Noriko Fukuhara,
Yasuhito Terui,
Tatsuro Jo,
Go Yamamoto,
Takayuki Ishikawa,
Tsutomu Kobayashi,
Toru Kiguchi,
Hirokazu Nagai,
Tomoko Ohtsu,
Stacey Kalambakas,
Pierre Fustier,
Shuichi Midorikawa,
Kensei Tobinai
,
Yosuke Minami,
Noriko Fukuhara,
Yasuhito Terui,
Tatsuro Jo,
Go Yamamoto,
Takayuki Ishikawa,
Tsutomu Kobayashi,
Toru Kiguchi,
Hirokazu Nagai,
Tomoko Ohtsu,
Stacey Kalambakas,
Pierre Fustier,
Shuichi Midorikawa,
Kensei Tobinai
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 